The Institute for Clinical and Economic Review (ICER) has released the slate of new drugs it plans to review in 2016. These reviews are a continuation of the new drug assessment program begun in the Fall of 2015. The list of drugs to be reviewed is based on ICER’s discussion with multiple payers and other stakeholders to prioritize the most important new drugs in the pipeline with expected FDA approval between late 2015 andmid-2016. Due to the uncertain timing and outcomes of FDA decisions, ICER may revise this schedule as necessary.
Providing credible, evidence-based information about medical technologies, treatments, and models of care
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), reviews objective evidence reports and holds public meetings to develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care.
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.